Back to top

messenger-rna: Archive

Zacks Equity Research

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

SNYPositive Net Change GSKNegative Net Change MRKPositive Net Change MRNANegative Net Change

Zacks Equity Research

Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

SNYPositive Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change

Zacks Equity Research

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.

PFENegative Net Change LLYNegative Net Change FULCNegative Net Change BVSPositive Net Change